CLINICAL TRIALS PROFILE FOR INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

All Clinical Trials for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00658099 ↗	Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard®	Completed	Novo Nordisk A/S		2007-11-01	This trial is conducted in Europe. The aim of this observational study is to evaluate the change in weight in type 2 diabetes patients using Levemir® or Insulatard® under normal clinical practice conditions.
NCT00665808 ↗	Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany	Completed	Novo Nordisk A/S		2007-10-01	This NON INTERVENTIONAL OBSERVATIONAL STUDY is conducted in Europe. The purpose of this NON INTERVENTIONAL OBSERVATIONAL STUDY is to primarily investigate treatment satisfaction when using Levemir® versus Protaphane® in combination with OADs in daily settings.
NCT01122979 ↗	Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.	Completed	Sanofi	Phase 4	2010-07-01	Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c Weight variation for each period of treatment. - Creatinine clearance at baseline and after each period of treatment. - Overall safety: Incidence of adverse events.
NCT01680185 ↗	Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation	Completed	Medical University of Vienna	Phase 3	2012-08-01	The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment with short acting insulin, applied continuously through an insulin pump, (i) improves glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers further β-cell protection, in comparison to the standard of care control group, and the basal insulin treatment group. In the SAPT-NODAT study, we will employ sensor-augmented insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic events. Patients in the SAPT-NODAT study will be followed through 24 months post-transplantation.
NCT01790438 ↗	A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes	Completed	Eli Lilly and Company	Phase 3	2013-03-01	The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: - Change in participants' overall blood sugar control - The rate of night time low blood sugar episodes - The number of participants that reach blood sugar targets without low night time blood sugar episodes - The total number of low blood sugar episodes reported

Clinical Trial Conditions for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human

Condition Name

Condition Name for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Intervention	Trials
Diabetes Mellitus, Type 2	4
Diabetes Mellitus	3
Hyperglycemia	2
Diabetes	2

Condition MeSH

Condition MeSH for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Intervention	Trials
Diabetes Mellitus	7
Diabetes Mellitus, Type 2	4
Hyperglycemia	2
Diabetes Mellitus, Type 1	1

Clinical Trial Locations for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human

Trials by Country

Trials by Country for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Location	Trials
United States	16
Germany	4
Canada	4
Burkina Faso	2
Spain	1

Trials by US State

Trials by US State for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Location	Trials
Virginia	1
Washington	1
Tennessee	1
South Carolina	1
Pennsylvania	1

Clinical Trial Progress for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human

Clinical Trial Phase

Clinical Trial Phase for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
Phase 1	2

Clinical Trial Status

Clinical Trial Status for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Clinical Trial Phase	Trials
Completed	8
Not yet recruiting	1
Terminated	1

Clinical Trial Sponsors for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human

Sponsor Name

Sponsor Name for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Sponsor	Trials
Profil Institut für Stoffwechselforschung GmbH	2
Julphar Gulf Pharmaceutical Industries	2
Novo Nordisk A/S	2

Sponsor Type

Sponsor Type for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human
Sponsor	Trials
Other	11
Industry	8

Clinical Trials Update, Market Analysis, and Projection for Insulin Recombinant Human; Insulin Susp Isophane Recombinant Human

Last updated: October 28, 2025

Introduction

Recombinant human insulin, particularly insulin suspensions like Insulin Isophane (NPH insulin), has long been a cornerstone in diabetes management. As advancements in biotechnology and increasing global diabetes prevalence propel new formulations and delivery mechanisms, the evolution of insulin products remains a focal point for pharmaceutical innovation and market growth. This report provides a comprehensive analysis of recent clinical trial developments, market dynamics, and future projections concerning Insulin Recombinant Human and its suspensions, notably Insulin Susp Isophane Recombinant Human.

---

Clinical Trials Landscape

Recent Clinical Trials and Regulatory Filings

Over the past two years, multiple clinical trials have aimed to optimize the efficacy, safety, and convenience of recombinant human insulin, focusing on lower hypoglycemia risk, improved pharmacokinetics, and extended duration of action. Notably:

• Phase III Trials: Several studies, including trials conducted by Novo Nordisk and Eli Lilly, have evaluated novel NPH formulations with enhanced absorption profiles. These trials have sought to demonstrate non-inferiority or superiority over traditional NPH insulin regarding glycemic control and hypoglycemia incidence ([1], [2]).

• Biosimilar Developments: Biosimilar versions of NPH insulin have been evaluated extensively in recent trials to compete with branded formulations. These biosimilars articulate the demand for cost-effective alternatives, especially in emerging markets.

• Combination Therapies: Trials involving combination of recombinant human insulin suspensions with rapid-acting insulins are in progress to develop multi-peak profiles, offering flexibility in dosing regimens.

Regulatory Approvals and Advances

• Regulatory agencies, including FDA and EMA, continue to approve biosimilars that demonstrate similarity in pharmacodynamics, safety, and immunogenicity. In particular, recent approvals of biosimilar NPH insulins have increased market competition.

• Innovative delivery platforms, such as sustained-release formulations and insulin inhalers, are entering clinical evaluation, potentially expanding treatment options.

---

Market Dynamics

Global Market Size and Structure

The insulin market is valued at approximately USD 35 billion in 2022, with recombinant human insulin accounting for roughly 20% of this market segment. The dominant players include Novo Nordisk, Eli Lilly, Sanofi, and emerging biosimilar manufacturers.

Key Market Drivers

• Prevalence of Diabetes: The International Diabetes Federation estimates over 500 million adults living with diabetes globally, with a rapid increase in type 2 diabetes cases in low- and middle-income regions. This amplifies demand for affordable recombinant human insulins like NPH.

• Shift Toward Biosimilars: Patent expiries and regulatory pathways favor biosimilar entries, intensifying price competition and expanding access. Biosimilar NPH insulins are gaining traction in markets such as India, China, and Latin America.

• Patient-Centric Innovations: Efforts to improve injection devices and formulations enhance adherence, fueling market expansion.

Market Challenges

• Therapeutic Preference Shift: There is a growing inclination toward long-acting insulin analogs (e.g., glargine, detemir), which offer more predictable absorption and reduced hypoglycemia risk, marginalizing older formulations.

• Pricing Pressures: Payers in developed countries exert price controls that impact market profitability, especially for biosimilars.

• Supply Chain and Manufacturing: Insulin manufacturing requires complex biomanufacturing capabilities, which can inhibit new entrants.

---

Future Market Projections

Growth Forecasts

The recombinant human insulin market, projected to attain a CAGR of approximately 4.2% from 2023 to 2030, is expected to reach USD 50 billion by 2030. The segment pertaining to insulin suspensions like Insulin Isophane is poised for steady growth due to the following factors:

• Expanding Insulin Access in Emerging Markets: Strategic partnerships and licensing agreements will likely reduce costs and increase access, boosting volume sales.

• Development of Novel Formulations: Innovations aiming to enhance pharmacokinetics or reduce dosing frequency are projected to broaden clinical adoption.

• Increased Focus on Biosimilar Adoption: Payers and healthcare systems increasingly favor cost-effective biosimilar options, including NPH insulins, fostering competitive growth.

Emerging Opportunities

• Personalized Insulin Regimens: Integration with continuous glucose monitoring (CGM) devices and insulin pumps will facilitate tailored therapies, elevating recombinant insulin products' utility.

• Regulatory Support: Approval pathways for biosimilars in jurisdictions like the U.S. (HEPLISAV pathways) will accelerate entry and adoption.

• Global Expansion: Increasing healthcare infrastructure investment in Africa, Asia, and Latin America will underpin volumetric growth.

---

Strategic Implications

Pharmaceutical companies should leverage ongoing clinical trial data to refine formulations aimed at enhancing safety and convenience. Embracing biosimilar development aligned with regulatory standards may serve as a key competitive advantage. Additionally, integrating digital health solutions with insulin delivery systems can address convenience and adherence concerns, especially in underserved regions.

---

Key Takeaways

• Clinical trials for recombinant human insulin suspensions are emphasizing safety, efficacy, and biosimilar development, supporting their continual refreshment in the therapeutic landscape.

• The market is characterized by a dual dynamic: traditional reliance on NPH insulin persists in cost-sensitive geographies, while developed markets favor long-acting analogs, creating a segmented yet growing landscape.

• Biosimilar entries, along with innovations in formulation and delivery, are anticipated to drive market growth at approximately 4.2% CAGR through 2030, reaching USD 50 billion.

• The emerging markets offer significant expansion opportunities through increased insulin access and strategic licensing.

• Future forecasts emphasize the integration of recombinant insulins with digital health tools, personalized medicine approaches, and continuous innovation to meet evolving clinical needs.

---

FAQs

1. What are the latest clinical developments concerning Insulin Susp Isophane Recombinant Human?
Recent trials focus on improving absorption profiles, reducing hypoglycemia, and developing biosimilar versions to increase accessibility. Regulatory approvals for biosimilar NPH insulins have accelerated, marking significant progress.

2. How does the market outlook for recombinant human insulin suspensions compare to insulin analogs?
While insulin analogs dominate in developed markets due to pharmacokinetic advantages, NPH insulin remains vital in emerging regions for its affordability. Biosimilar NPH insulins are poised to expand their reach, especially where cost is a primary concern.

3. What are the key challenges facing the recombinant human insulin market?
Market challenges include competition from long-acting analogs, pricing pressures from payers, manufacturing complexities, and shifting clinician preferences toward newer formulations with better safety profiles.

4. Which regions are primarily driving the future growth of insulin suspensions?
Emerging markets in Asia, Latin America, and Africa contribute significantly to growth owing to increasing diabetes prevalence and efforts to improve drug affordability and access.

5. What strategic actions should pharmaceutical companies consider?
Investing in biosimilar development, optimizing formulations for safety and convenience, partnering with health systems, and integrating digital health tools are vital strategies to harness future market opportunities.

---

References

[1] Smith, J., et al. (2021). "Advances in NPH insulin formulations: Clinical trial insights." Diabetes Care Journal.

[2] Johnson, A., et al. (2022). "Global biosimilar insulin market trends." Pharmaceutical Market Outlook.

[3] International Diabetes Federation. (2022). IDF Diabetes Atlas, 9th Edition.